Shukra Pharmaceuticals's total inventories for the quarter that ended in Mar. 2026 was ₹139.0 Mil. Shukra Pharmaceuticals's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was ₹69.5 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Shukra Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was ₹0.06.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Shukra Pharmaceuticals's Days Inventory for the
three
months ended in Mar. 2026 was 106.79.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Shukra Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.85.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Shukra Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 1.10.
Shukra Pharmaceuticals (BOM:524632) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Shukra Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Shukra Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Shukra Pharmaceuticals Total Inventories Related Terms
Shukra Pharmaceuticals Total Inventories Historical Data
* Premium members only.
The historical data trend for Shukra Pharmaceuticals's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shukra Pharmaceuticals Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Shukra Pharmaceuticals (BOM:524632) has a Total Inventories of ₹139.0 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Shukra Pharmaceuticals and its competitors.
Is Shukra Pharmaceuticals' Total Inventories too high?
Shukra Pharmaceuticals' current Total Inventories is ₹139.0 Mil. Overall, Shukra Pharmaceuticals has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shukra Pharmaceuticals' Total Inventories compare to ZTS and UTHR?
Shukra Pharmaceuticals' Total Inventories of ₹139.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Shukra Pharmaceuticals and its competitors. Shukra Pharmaceuticals's current Total Inventories is ₹139.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shukra Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Shukra Pharmaceuticals (BOM:524632) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹8.69, compared to a current price of ₹31.68 — trading 264.6% above its estimated fair value. The current Total Inventories is ₹139.0 Mil. Shukra Pharmaceuticals' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Shukra Pharmaceuticals (BOM:524632), the current Total Inventories is ₹139.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shukra Pharmaceuticals (BOM:524632) Overvalued in 2026?
Based on GuruFocus' analysis, Shukra Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹31.68 is trading 264.6% above its estimated GF Value™ of ₹8.69.
GuruFocus considers Shukra Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:524632:
Total Inventories: ₹139.0 Mil
GF Value™: ₹8.69 vs. price of ₹31.68 (264.6% above fair value)
No single metric tells the full story. See the BOM:524632 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments: Pharmaceutical and Laboratory. Its product portfolio includes antibiotics, quinolones, macrolides, antibacterials, antifungals, antimalarials, antivirals, antiprotozoals, anthelmintics, antidepressants, antimanics, antiemetics, beta-blockers, analgesics, muscle relaxants, antituberculosis agents, vitamin products, antiallergics, corticosteroids, hyperglycemic and hypoglycemic agents, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.
66GF Score
Get the complete analysis for BOM:524632
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524632 has been successfully added to your 
